Author's response to reviews

Title: VEGFR-3 and CXCR4 as predictive markers for treatment with fluorouracil, leucovorin plus either oxaliplatin or cisplatin in patients with advanced esophagogastric cancer: a comparative study of the Arbeitsgemeinschaft Internistische Onkologie (AIO).

Authors:

Thomas Thomaidis (tomagiot@hotmail.com)
Annett Maderer (annett.maderer@unimedizin-mainz.de)
Salah-Eddin Al-Batran (albatran@aol.com)
Janis Kany (jakany@web.de)
Claudia Pauligk (pauligk.claudia@khnw.de)
Kristina Steinmetz (steinmetz.kristina@khnw.de)
Arno Schad (Arno.Schad@unimedizin-mainz.de)
Ralf Hofheinz (ralf.hofheinz@umm.de)
Harald Schmalenberg (Harald.Schmalenberg@med.uni-jena.de)
Nils Homann (niils.homann@klinikum.wolfsburg.de)
Peter R Galle (Peter.Galle@unimedizin-mainz.de)
Markus Moehler (Markus.Moehler@unimedizin-mainz.de)

Version: 4 Date: 13 May 2014

Author's response to reviews: see over
Dear Sir and Madam,

In the last editorial letter you kindly gave us the opportunity to resubmit our manuscript after minor changes. Thank you again for considering our manuscript for publication in *BMC Cancer*.

Following this review process we concordantly changed the manuscript. We agree to the Editorial Board’s encouragements and added more details in the method section for the IHC part (point 2). Additionally, we again checked our manuscript for errors (point 3) and adapt it to the specific journal style.

The REMARK criteria are already anchored in the text (page 15) and additionally in table 3 (page 28). The REMARK guidelines are referring mainly to prognostic marker studies. Although our study investigates the predictive value of tumour biomarkers, we adjusted our manuscript in dependence to the article of Lisa M. McShane et al. (point 1).

Thus, we re-submit the manuscript with the amendments marked in tracked changes and attached this short point by point response to the Editorial Board in time. We truly hope that the manuscript can now be accepted in its present version.

If you have further questions don’t hesitate to contact us. We thank you for reconsidering our manuscript for *BMC Cancer*.

Yours sincerely

Thomas Thomaidis